+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hemp-based Products - Global Strategic Business Report

  • PDF Icon

    Report

  • 386 Pages
  • October 2026
  • Region: Global
  • Market Glass, Inc.
  • ID: 6099420
The global market for Hemp-based Products was valued at US$6.1 Billion in 2025 and is projected to reach US$18.1 Billion by 2032, growing at a CAGR of 16.8% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Hemp-Based Products Market - Key Trends & Drivers Summarized

Why Are Hemp-Based Products Rising in Popularity Across Multiple Consumer Sectors?

Hemp-based products are rapidly gaining global traction due to their sustainability, versatility, and wide range of applications across wellness, textiles, food, construction, and personal care. Derived from industrial hemp (Cannabis sativa L.), these products contain minimal THC and are legally cultivated in many regions for their eco-friendly characteristics and health benefits. Hemp seed oil, protein powder, clothing, bioplastics, paper, and CBD-infused wellness products are transforming the plant into a powerful economic and environmental commodity.

Consumer interest in natural, plant-based alternatives is driving demand for hemp in skincare, nutritional supplements, and eco-friendly materials. In food and beverage sectors, hemp is being positioned as a superfood rich in omega-3, fiber, and plant protein. Meanwhile, the personal care industry is embracing hemp-derived oils for their moisturizing and anti-inflammatory properties. With growing environmental consciousness and demand for organic labels, hemp has emerged as a sustainable raw material that resonates with ethical consumers.

How Are Regulations and Supply Chain Developments Shaping Product Commercialization?

The legalization and regulatory standardization of industrial hemp cultivation and processing - especially in the U.S., Canada, parts of Europe, and increasingly in Asia-Pacific - have opened the door for large-scale commercialization. Improved agricultural practices, government support, and investment in hemp processing technologies have streamlined supply chains, reduced costs, and increased availability of quality raw materials.

Technologies such as decorticators, fiber extractors, and CBD oil extraction equipment are enabling efficient value addition across sectors. At the same time, global regulations governing cannabinoid content and labeling requirements for CBD products are prompting brands to invest in product standardization, testing, and traceability. Blockchain-based supply chains and third-party certification systems are further strengthening transparency and consumer trust, especially in wellness and health-related applications.

Which Industries and Regions Are Fueling Demand for Hemp-Based Solutions?

Health and wellness is the largest end-use sector for hemp, encompassing dietary supplements, functional beverages, topical applications, and therapeutic oils. The textile industry is another major consumer, replacing cotton and synthetic fibers with durable, breathable hemp alternatives. The construction sector is exploring hempcrete (hemp-based concrete) for its carbon-negative potential and insulation properties. In packaging and automotive industries, hemp-based bioplastics are emerging as eco-friendly materials that can replace petroleum-derived products.

North America remains the largest market, with the U.S. leading hemp-based CBD and food product innovation. Europe is expanding rapidly, especially in organic textiles and sustainable construction. Asia-Pacific, particularly China and India, is a key supplier of raw hemp and is witnessing growing domestic application in textiles, ayurveda, and bioplastics. Latin America and Africa are exploring hemp cultivation for rural development and industrial use, supported by favorable climate and untapped land resources.

The Growth in the Hemp-Based Products Market Is Driven by Several Factors

The growth in the hemp-based products market is driven by several factors tied to sustainable material demand, consumer wellness trends, and regulatory liberalization. Technological advancements in hemp cultivation, fiber processing, and cannabinoid extraction are enabling high-quality, scalable product development across categories. Supply chain maturity and regulatory frameworks have also improved, facilitating global trade and brand expansion.

From an end-use standpoint, rising interest in clean-label, natural health products is fueling the uptake of hemp-based foods, supplements, and personal care items. Sustainability mandates and carbon footprint reduction efforts are driving adoption in fashion, construction, and packaging sectors. Additionally, the alignment of hemp with organic farming practices, circular economy goals, and plant-based lifestyle movements is reinforcing its role as a transformative ingredient in future-ready industries.

Report Scope

The report analyzes the Hemp-based Products market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:
  • Segments: Product Type (Food Product Type, HEMP CBD Product Type, Personal Care Product Type, Industrial Products Product Type, Food Supplement Product Type, Consumer Textiles Product Type, Other Product Types); End-Use (Industrial End-Use, Commercial End-Use, Residential End-Use); Distribution Channel (Online Distribution Channel, Offline Distribution Channel)
  • Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Food Product Type segment, which is expected to reach US$4.6 Billion by 2032 with a CAGR of a 16.7%. The HEMP CBD Product Type segment is also set to grow at 17.9% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $1.7 Billion in 2025, and China, forecasted to grow at an impressive 21.6% CAGR to reach $4.0 Billion by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Hemp-based Products Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Hemp-based Products Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Hemp-based Products Market expected to evolve by 2032?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2032?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Aurora Cannabis Inc., Bluebird Botanicals, Canopy Growth Corporation, Charlotte's Web Holdings, Inc., Curaleaf Holdings, Inc. and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Hemp-based Products market report include:

  • Aurora Cannabis Inc.
  • Bluebird Botanicals
  • Canopy Growth Corporation
  • Charlotte's Web Holdings, Inc.
  • Curaleaf Holdings, Inc.
  • Ecofibre Limited
  • Elixinol Global Limited
  • GenCanna Global Inc.
  • Green Thumb Industries
  • Hemp, Inc.
  • HempFlax Group B.V.
  • HempFusion Wellness Inc.
  • Manitoba Harvest
  • MH medical hemp GmbH
  • Nutiva Inc.
  • Parkland Industrial Hemp Growers Co-op Ltd.
  • PharmaHemp d.o.o.
  • Tilray Brands, Inc.
  • Valley Bio Limited
  • Victory Hemp Foods

What Sets This Report Apart From Others?

  • Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
  • Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
  • Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
  • Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
  • Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
  • Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, the report extends market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • World Market Trajectories
  • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
  • Hepatitis A Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Global Awareness of Vaccine-Preventable Diseases Drives Uptake of Hepatitis A Vaccination Programs
  • Increasing Incidence of Hepatitis A Outbreaks in Low-to-Middle-Income Regions Spurs Mass Immunization Campaigns
  • Inclusion of Hepatitis A Vaccines in National Immunization Schedules Expands Access and Public Sector Procurement
  • Growth in International Travel and Tourism Encourages Preventive Vaccination Among High-Risk Populations
  • Expansion of Pediatric Vaccination Coverage Globally Supports Early Immunization Against Hepatitis A
  • Combination Vaccines Featuring Hepatitis A and B Enhance Compliance and Broaden Market Reach
  • Support From Global Health Agencies and NGOs Strengthens Funding for Vaccination in Endemic Areas
  • Advancements in Cold Chain Infrastructure Improve Vaccine Distribution in Remote and Underserved Locations
  • Rising Demand for Adult and Occupational Vaccination Fuels Non-Pediatric Market Growth
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Hepatitis A Vaccines Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2032
  • Table 2: World Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 3: World Historic Review for Hepatitis A Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 4: World 13-Year Perspective for Hepatitis A Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
  • Table 5: World Recent Past, Current & Future Analysis for Inactivated Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 6: World Historic Review for Inactivated Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 7: World 13-Year Perspective for Inactivated Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 8: World Recent Past, Current & Future Analysis for Live Attenuated Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 9: World Historic Review for Live Attenuated Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 10: World 13-Year Perspective for Live Attenuated Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 11: World Recent Past, Current & Future Analysis for Government Institution by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 12: World Historic Review for Government Institution by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 13: World 13-Year Perspective for Government Institution by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 14: World Recent Past, Current & Future Analysis for Private Sector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 15: World Historic Review for Private Sector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 16: World 13-Year Perspective for Private Sector by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 17: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 18: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 19: World 13-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
III. MARKET ANALYSIS
UNITED STATES
  • Hepatitis A Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
  • Table 20: USA Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 21: USA Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 22: USA 13-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2020, 2026 & 2032
  • Table 23: USA Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 24: USA Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 25: USA 13-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2020, 2026 & 2032
CANADA
  • Table 26: Canada Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 27: Canada Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 28: Canada 13-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2020, 2026 & 2032
  • Table 29: Canada Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 30: Canada Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 31: Canada 13-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2020, 2026 & 2032
JAPAN
  • Hepatitis A Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
  • Table 32: Japan Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 33: Japan Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 34: Japan 13-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2020, 2026 & 2032
  • Table 35: Japan Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 36: Japan Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 37: Japan 13-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2020, 2026 & 2032
CHINA
  • Hepatitis A Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
  • Table 38: China Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 39: China Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 40: China 13-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2020, 2026 & 2032
  • Table 41: China Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 42: China Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 43: China 13-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2020, 2026 & 2032
EUROPE
  • Hepatitis A Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
  • Table 44: Europe Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 45: Europe Historic Review for Hepatitis A Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 46: Europe 13-Year Perspective for Hepatitis A Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020, 2026 & 2032
  • Table 47: Europe Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 48: Europe Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 49: Europe 13-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2020, 2026 & 2032
  • Table 50: Europe Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 51: Europe Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 52: Europe 13-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2020, 2026 & 2032
FRANCE
  • Hepatitis A Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
  • Table 53: France Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 54: France Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 55: France 13-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2020, 2026 & 2032
  • Table 56: France Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 57: France Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 58: France 13-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2020, 2026 & 2032
GERMANY
  • Hepatitis A Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
  • Table 59: Germany Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 60: Germany Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 61: Germany 13-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2020, 2026 & 2032
  • Table 62: Germany Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 63: Germany Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 64: Germany 13-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2020, 2026 & 2032
ITALY
  • Table 65: Italy Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 66: Italy Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 67: Italy 13-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2020, 2026 & 2032
  • Table 68: Italy Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 69: Italy Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 70: Italy 13-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2020, 2026 & 2032
UNITED KINGDOM
  • Hepatitis A Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
  • Table 71: UK Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 72: UK Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 73: UK 13-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2020, 2026 & 2032
  • Table 74: UK Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 75: UK Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 76: UK 13-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2020, 2026 & 2032
SPAIN
  • Table 77: Spain Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 78: Spain Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 79: Spain 13-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2020, 2026 & 2032
  • Table 80: Spain Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 81: Spain Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 82: Spain 13-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2020, 2026 & 2032
RUSSIA
  • Table 83: Russia Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 84: Russia Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 85: Russia 13-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2020, 2026 & 2032
  • Table 86: Russia Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 87: Russia Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 88: Russia 13-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2020, 2026 & 2032
REST OF EUROPE
  • Table 89: Rest of Europe Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 90: Rest of Europe Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 91: Rest of Europe 13-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2020, 2026 & 2032
  • Table 92: Rest of Europe Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 93: Rest of Europe Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 94: Rest of Europe 13-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2020, 2026 & 2032
ASIA-PACIFIC
  • Hepatitis A Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
  • Table 95: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 96: Asia-Pacific Historic Review for Hepatitis A Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 97: Asia-Pacific 13-Year Perspective for Hepatitis A Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2020, 2026 & 2032
  • Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 99: Asia-Pacific Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 100: Asia-Pacific 13-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2020, 2026 & 2032
  • Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 102: Asia-Pacific Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 103: Asia-Pacific 13-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2020, 2026 & 2032
AUSTRALIA
  • Hepatitis A Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
INDIA
  • Hepatitis A Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Hepatitis A Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Hepatitis A Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Hepatitis A Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Aurora Cannabis Inc.
  • Bluebird Botanicals
  • Canopy Growth Corporation
  • Charlotte's Web Holdings, Inc.
  • Curaleaf Holdings, Inc.
  • Ecofibre Limited
  • Elixinol Global Limited
  • GenCanna Global Inc.
  • Green Thumb Industries
  • Hemp, Inc.
  • HempFlax Group B.V.
  • HempFusion Wellness Inc.
  • Manitoba Harvest
  • MH medical hemp GmbH
  • Nutiva Inc.
  • Parkland Industrial Hemp Growers Co-op Ltd.
  • PharmaHemp d.o.o.
  • Tilray Brands, Inc.
  • Valley Bio Limited
  • Victory Hemp Foods

Table Information